Rövid rekord

dc.contributor.authorErol, Büşra Burcu
dc.contributor.authorGülersoy, Erdem
dc.contributor.authorKoral, Erman
dc.date.accessioned2024-10-09T11:32:25Z
dc.date.available2024-10-09T11:32:25Z
dc.date.issued2024-10
dc.identifier.citationMagyar Állatorvosok Lapja 146(10), 603-614. (2024)en_US
dc.identifier.urihttp://hdl.handle.net/10832/4117
dc.description.abstractFeline panleukopenia (FP) is a highly contagious disease in cats, particularly affec- ting young and unvaccinated ones. Conventional treatments have a success rate below 50%. FPV severely impacts progenitor cells and all myeloid populations, leading to panleukopenia, making immune stimulation vital for treatment. This study aimed to evaluate the short-term effects of recombinant human granu- locyte colony-stimulating factor (rhG-CSF, filgrastim) on FP and update treatment protocols by assessing serum serotonin concentrations. 28 cats were treated: 14 with standard treatment and 14 with standard treatment plus filgrastim at 5 mcg/ kg twice daily. After 24 hours, granulocyte and serum serotonin concentrations in the Filgrastim group were higher than those in both the first admission and Standard treatment groups (p < 0.05). It was concluded that the administration of filgrastim stimulates blood progenitor cells, alleviates immunosuppression, and increases serum serotonin concentrations. Assessing serotonin concentrations may provide insights into inflammation and serves as a prognostic indicator for treatment response.en_US
dc.language.isohuen_US
dc.titleAz rhG-CSF használatának a szerotoninkoncentrációra gyakorolt rövid távú hatásai a macska panleukopeniájának kezelésébenen_US
dc.title.alternativeShort-Term Effects of rhG-CSF Use on Serotonin Concentration in the Treatment of Feline Panleukopeniaen_US
dc.typeArticleen_US
dc.identifier.doi10.56385/magyallorv.2024.10.603-614


A tételhez tartozó fájlok

Thumbnail

Ez a dokumentum a következő gyűjtemény(ek)hez tartozik:

Rövid rekord